June #124 : Oral Thursh Knockout - by Liz Highleyman

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Mentors-June 2006

A Growing Concern

Cover Q&A-June 2006

Supplemental Insurance

Oral Thursh Knockout

Med-Mix Warning

Chow, Babe

Tart Up Your PI

Food for Oil

Fatty Acid Trip

In the Key of Life

PREP School

PREP for the future

WAL-MART Special

Bush the Builder

The Domino Effect

Happy Birthday to Us

Can NYC Keep A Lid On AIDS?

Virgin Vaccine

Onward Christian Condoms


Raining Men

Positive Change

Growing Pains

Dolled Up

That ’80s Show

I See Dead People

Editor's Letter-June 2006

Mailbox-June 2006

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

June 2006

Oral Thursh Knockout

by Liz Highleyman

A new med may keep an old infection from making a comeback

In the early days of the epidemic, oral thrush was recognized as a defining emblem of HIV. The incidence of thrush has fallen dramatically with combo therapy, but it’s still the most common fungal infection in positive people. Now, a Wayne State University study has found that a new drug, Noxafil, has a cure rate of more than 90% and a relapse rate lower than that of other meds.

Caused by a yeastlike fungus (usually Candida albicans) that lives in healthy people, oral thrush can occur when the immune system weakens. Any HIV positive person can get it, but the risk rises as CD4s drop (especially below 300). The symptoms are white or red blotches on the tongue, gums and inner cheeks or painful cracks at the corners of the mouth. It can sneak down the throat and into the esophagus, making eating and swallowing excruciating.

Protease inhibitors (PIs) seem to block Candida: One study found that 7% of people taking PIs developed thrush, compared with 50% taking just nukes. Treatments include antifungals such as Mycelex (clotrimazole), Diflucan (fluconazole) and Sporanox (itraconazole), in the form of pills, lozenges or liquid to swish around in the mouth. (Natural  therapies include cutting back on sugar and cigarettes and eating yogurt with active cultures of the friendly bacteria Lactobacillus acidophilus.)

Candida often returns once treatment with available drugs is stopped. That’s where Noxafil comes in. Jose Vazquez, MD, who led the Wayne State study that followed 350 people worldwide, says Noxafil matched Diflucan’s cure rate but did better at preventing return engagements. Submitted for approval in February, Noxafil could be available by early 2007.  

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.